165 related articles for article (PubMed ID: 12543077)
1. SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells.
Lundin Brockdorff J; Woetmann A; Mustelin T; Kaltoft K; Zhang Q; Wasik MA; Röpke C; Ødum N
Cytokine; 2002 Nov; 20(4):141-7. PubMed ID: 12543077
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
3. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
4. Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a.
Brockdorff JL; Gu H; Mustelin T; Kaltoft K; Geisler C; Röpke C; Ødum N
Exp Clin Immunogenet; 2001; 18(2):86-95. PubMed ID: 11340297
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation.
Arnaud M; Crouin C; Deon C; Loyaux D; Bertoglio J
J Immunol; 2004 Sep; 173(6):3962-71. PubMed ID: 15356145
[TBL] [Abstract][Full Text] [Related]
6. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
7. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.
Hayakawa F; Towatari M; Iida H; Wakao H; Kiyoi H; Naoe T; Saito H
Br J Haematol; 1998 Jun; 101(3):521-8. PubMed ID: 9633897
[TBL] [Abstract][Full Text] [Related]
8. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways.
Lee K; Esselman WJ
Free Radic Biol Med; 2002 Oct; 33(8):1121-32. PubMed ID: 12374624
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.
Majka M; Ratajczak J; Villaire G; Kubiczek K; Marquez LA; Janowska-Wieczorek A; Ratajczak MZ
Exp Hematol; 2002 Jul; 30(7):751-60. PubMed ID: 12135673
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation.
Yu CL; Jin YJ; Burakoff SJ
J Biol Chem; 2000 Jan; 275(1):599-604. PubMed ID: 10617656
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells.
Kalina U; Koschmieder S; Hofmann WK; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
Exp Hematol; 2001 May; 29(5):602-8. PubMed ID: 11376873
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
15. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway.
Beadling C; Ng J; Babbage JW; Cantrell DA
EMBO J; 1996 Apr; 15(8):1902-13. PubMed ID: 8617237
[TBL] [Abstract][Full Text] [Related]
17. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling.
Tanuma N; Shima H; Nakamura K; Kikuchi K
Blood; 2001 Nov; 98(10):3030-4. PubMed ID: 11698287
[TBL] [Abstract][Full Text] [Related]
19. Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling.
Paling NR; Welham MJ
Biochem J; 2002 Dec; 368(Pt 3):885-94. PubMed ID: 12220225
[TBL] [Abstract][Full Text] [Related]
20. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.
Kanie T; Abe A; Matsuda T; Kuno Y; Towatari M; Yamamoto T; Saito H; Emi N; Naoe T
Leukemia; 2004 Mar; 18(3):548-55. PubMed ID: 14749700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
